CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells

Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield us...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Immunol Res
Autori principali: Du, Juan, Lopez-Verges, Sandra, Pitcher, Brandelyn N., Johnson, Jeffrey, Jung, Sin-Ho, Zhou, Lili, Hsu, Katharine, Czuczman, Myron S., Cheson, Bruce, Kaplan, Lawrence, Lanier, Lewis L., Venstrom, Jeffrey M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4264658/
https://ncbi.nlm.nih.gov/pubmed/24958280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0158
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi